We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.1B
AUM Growth
-$787M
Cap. Flow
+$233M
Cap. Flow %
2.56%
Top 10 Hldgs %
30.12%
Holding
189
New
31
Increased
28
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
IVVD icon
Invivyd
IVVD
+$200M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
BIIB icon
Biogen
BIIB
+$54.7M
4
HCA icon
HCA Healthcare
HCA
+$47.4M
5
MREO
Mereo BioPharma
MREO
+$45.7M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$78.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$58.9M
3
NTRA icon
Natera
NTRA
+$55.6M
4
ELV icon
Elevance Health
ELV
+$48.9M
5
BSX icon
Boston Scientific
BSX
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$382M 4.2%
6,028,307
-15,959
-0.3% -$1.23M
PRLD icon
2
Prelude Therapeutics
PRLD
$370M
$314M 3.45%
10,039,691
– –
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$286M 3.14%
2,610,355
-311,800
-11% -$32.4M
MRK icon
4
Merck
MRK
$326B
$280M 3.08%
3,732,400
– –
BMY icon
5
Bristol-Myers Squibb
BMY
$130B
$267M 2.94%
4,515,400
– –
BSX icon
6
Boston Scientific
BSX
$68.5B
$253M 2.78%
5,833,600
-1,087,000
-16% -$48.1M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$243M 2.67%
1,373,200
+109,000
+9% +$17.5M
EWTX icon
8
Edgewise Therapeutics
EWTX
$4.34B
$231M 2.54%
13,944,680
– –
IVVD icon
9
Invivyd
IVVD
$175M
$227M 2.5%
+5,383,500
New +$200M
PMVP icon
10
PMV Pharmaceuticals
PMVP
$58.7M
$218M 2.4%
7,330,423
– –
NTRA icon
11
Natera
NTRA
$36.1B
$175M 1.93%
1,572,800
-485,000
-24% -$55.6M
IOVA icon
12
Iovance Biotherapeutics
IOVA
$2.1B
$164M 1.8%
6,645,100
– –
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$124B
$159M 1.75%
877,400
-188,000
-18% -$36.7M
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$157M 1.72%
2,361,327
– –
GH icon
15
Guardant Health
GH
$19B
$153M 1.69%
1,227,400
– –
ABBV icon
16
AbbVie
ABBV
$465B
$153M 1.68%
1,420,600
+253,100
+22% +$28.9M
UNH icon
17
UnitedHealth
UNH
$389B
$152M 1.67%
389,700
– –
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.55B
$145M 1.59%
6,073,850
– –
ISRG icon
19
Intuitive Surgical
ISRG
$130B
$139M 1.53%
418,800
– –
XBI icon
20
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$134M 1.47%
1,065,700
+130,000
+14% +$16.7M
HUM icon
21
Humana
HUM
$46.7B
$130M 1.43%
335,000
– –
EW icon
22
Edwards Lifesciences
EW
$48.2B
$128M 1.4%
1,126,400
– –
DXCM icon
23
DexCom
DXCM
$28.9B
$125M 1.37%
912,000
-277,600
-23% -$35M
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.4B
$114M 1.26%
1,192,015
-39,100
-3% -$3.69M
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$109M 1.2%
7,884,870
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2021 Portfolio in Review

As of Q3 2021, OrbiMed held 189 positions worth $9.1B, down 8% from $9.89B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q3 2021 filing shows 31 new, 28 increased, 27 reduced and 17 closed positions. Its largest new stake was Invivyd: 5,383,500 shares worth $227M. The largest sale was Aurinia Pharmaceuticals, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology.

  • OrbiMed's largest Q3 2021 buy was Invivyd: 5,383,500 shares worth $227M.
  • OrbiMed added most to Biogen in Q3 2021, an estimated $54.7M increase.
  • OrbiMed's biggest Q3 2021 reduction was Natera, cutting an estimated $55.6M.
  • OrbiMed fully exited Aurinia Pharmaceuticals in Q3 2021, selling an estimated $78.7M.
  • OrbiMed's ten largest holdings make up 30% of its $9.1B portfolio in Q3 2021.
  • OrbiMed opened 31 new positions and closed 17 in Q3 2021.
  • OrbiMed's portfolio value fell 8% quarter-over-quarter to $9.1B.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.